RxDoctor Payments Data

Alok Katyal, MD

Interventional Cardiology · Bridgeton, MONPI 1871551887

Payments from drug & device makers

$5,321in general payments, 2019–2025

Across 299 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Abiomed$434
  • Amgen$371
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$332
  • Cardiovascular Systems Inc.$320
  • Merck$241
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$5,308100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,321 in reported general payments places this provider in the 25th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$291,670
Medicare patients
472
Services billed
2,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan91$117,727
EliquisApixaban123$112,592
XareltoRivaroxaban72$93,882
FarxigaDapagliflozin Propanediol59$59,329
JardianceEmpagliflozin36$43,374
BrilintaTicagrelor35$32,503
OzempicSemaglutide17$25,850
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine38$6,669
Prasugrel Hcl34$4,108
Atorvastatin Calcium424$3,425
Metoprolol Succinate210$2,306
Carvedilol250$1,951
ClopidogrelClopidogrel Bisulfate202$1,834
Diltiazem 24hr Er (Cd)Diltiazem Hcl47$1,817
Bisoprolol Fumarate70$1,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,050$117,72791 claims
PfizerEliquis$99$112,592123 claims
Johnson & JohnsonXarelto$51$93,88272 claims
AstraZenecaFarxiga, Brilinta$135$91,83294 claims
Boehringer IngelheimJardiance$61$43,37436 claims
Novo NordiskOzempic$230$25,85017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Bridgeton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →